| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A graphic memoir: Probably Nothing
|
Lucas, Catherine
|
|
2015
|
16 |
1 |
p. 21-
1 p.
|
artikel
|
| 2 |
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials
|
Garcia, José M
|
|
2015
|
16 |
1 |
p. 108-116
9 p.
|
artikel
|
| 3 |
A new standard of care for metastatic melanoma?
|
Sharma, Sharan Prakash
|
|
2015
|
16 |
1 |
p. e8-
1 p.
|
artikel
|
| 4 |
Anti-PD-L1 antibody active in metastatic bladder cancer
|
Brower, Vicki
|
|
2015
|
16 |
1 |
p. e11-
1 p.
|
artikel
|
| 5 |
Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review
|
Markar, Sheraz R
|
|
2015
|
16 |
1 |
p. e23-e31
nvt p.
|
artikel
|
| 6 |
A well-earned death
|
Stirrups, Rob
|
|
2015
|
16 |
1 |
p. 21-22
2 p.
|
artikel
|
| 7 |
Barefoot to Billionaire
|
Burki, Talha Khan
|
|
2015
|
16 |
1 |
p. 22-23
2 p.
|
artikel
|
| 8 |
Blinatumomab: a new era of treatment for adult ALL?
|
Thomas, Xavier
|
|
2015
|
16 |
1 |
p. 6-7
2 p.
|
artikel
|
| 9 |
Breast cancer vaccine shows promise
|
Tanday, Sanjay
|
|
2015
|
16 |
1 |
p. e11-
1 p.
|
artikel
|
| 10 |
Cancer and high body-mass index: global burden, global effort?
|
Cairns, Benjamin J
|
|
2015
|
16 |
1 |
p. 3-4
2 p.
|
artikel
|
| 11 |
CDK4/6 inhibitors in luminal breast cancer
|
Gnant, Michael
|
|
2015
|
16 |
1 |
p. 2-3
2 p.
|
artikel
|
| 12 |
Correction to Lancet Oncol 2014; 15: 1195–206
|
|
|
2015
|
16 |
1 |
p. e6-
1 p.
|
artikel
|
| 13 |
Correction to Lancet Oncol 2015; 16: 91
|
|
|
2015
|
16 |
1 |
p. e6-
1 p.
|
artikel
|
| 14 |
Correction to Lancet Oncol 2015; 16: 52
|
|
|
2015
|
16 |
1 |
p. e6-
1 p.
|
artikel
|
| 15 |
Correction to Lancet Oncol 2012; 13: 817, 818, 822
|
|
|
2015
|
16 |
1 |
p. e6-
1 p.
|
artikel
|
| 16 |
European Commission drops scientific advisor
|
Burki, Talha Khan
|
|
2015
|
16 |
1 |
p. e7-
1 p.
|
artikel
|
| 17 |
Expanded access programmes: patient interests versus clinical trial integrity
|
Lorigan, Paul
|
|
2015
|
16 |
1 |
p. 15-17
3 p.
|
artikel
|
| 18 |
Fashion Descience project
|
Vibert-Stokes, Leila
|
|
2015
|
16 |
1 |
p. 23-24
2 p.
|
artikel
|
| 19 |
Galeterone activity in castration-resistant prostate cancer
|
Yaqub, Farhat
|
|
2015
|
16 |
1 |
p. e10-
1 p.
|
artikel
|
| 20 |
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
|
Arnold, Melina
|
|
2015
|
16 |
1 |
p. 36-46
11 p.
|
artikel
|
| 21 |
How to bat a curve ball
|
Morgan, Jules
|
|
2015
|
16 |
1 |
p. 24-
1 p.
|
artikel
|
| 22 |
IBIS-I tamoxifen update: maturity brings questions
|
Chlebowski, Rowan T
|
|
2015
|
16 |
1 |
p. 7-9
3 p.
|
artikel
|
| 23 |
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
|
Sternberg, Cora N
|
|
2015
|
16 |
1 |
p. 76-86
11 p.
|
artikel
|
| 24 |
Inhibition of mutant IDH1 in acute myeloid leukaemia
|
Yaqub, Farhat
|
|
2015
|
16 |
1 |
p. e9-
1 p.
|
artikel
|
| 25 |
Looking for predictive markers in breast cancer
|
Bonotto, Marta
|
|
2015
|
16 |
1 |
p. e1-
1 p.
|
artikel
|
| 26 |
Looking for predictive markers in breast cancer – Authors' reply
|
Gligorov, Joseph
|
|
2015
|
16 |
1 |
p. e1-e2
nvt p.
|
artikel
|
| 27 |
Lung cancer screening with low-dose CT: more questions than answers
|
Ruano-Ravina, Alberto
|
|
2015
|
16 |
1 |
p. e3-e4
nvt p.
|
artikel
|
| 28 |
Lung cancer screening with low-dose CT: more questions than answers – Author's reply
|
Mulshine, James L
|
|
2015
|
16 |
1 |
p. e4-
1 p.
|
artikel
|
| 29 |
Nivolumab success in untreated metastatic melanoma
|
Wilkinson, Emma
|
|
2015
|
16 |
1 |
p. e9-
1 p.
|
artikel
|
| 30 |
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
|
Oza, Amit M
|
|
2015
|
16 |
1 |
p. 87-97
11 p.
|
artikel
|
| 31 |
Oncology drug market worth predicted to increase
|
Burki, Talha Khan
|
|
2015
|
16 |
1 |
p. e10-
1 p.
|
artikel
|
| 32 |
Organ preservation in rectal cancer: have all questions been answered?
|
Marijnen, Corrie A M
|
|
2015
|
16 |
1 |
p. e13-e22
nvt p.
|
artikel
|
| 33 |
Osteosarcoma: better treatment through better trial design
|
Benjamin, Robert S
|
|
2015
|
16 |
1 |
p. 12-13
2 p.
|
artikel
|
| 34 |
Outcomes and endpoints in cancer trials: bridging the divide
|
Wilson, Michelle K
|
|
2015
|
16 |
1 |
p. e43-e52
nvt p.
|
artikel
|
| 35 |
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
|
Wilson, Michelle K
|
|
2015
|
16 |
1 |
p. e32-e42
nvt p.
|
artikel
|
| 36 |
PARP inhibitors in BRCA mutation-associated ovarian cancer
|
Clamp, Andrew
|
|
2015
|
16 |
1 |
p. 10-12
3 p.
|
artikel
|
| 37 |
POT1: a genetic link for familial glioma
|
Bagcchi, Sanjeet
|
|
2015
|
16 |
1 |
p. e12-
1 p.
|
artikel
|
| 38 |
PSA testing for prostate cancer screening
|
Castle, Philip E
|
|
2015
|
16 |
1 |
p. e2-e3
nvt p.
|
artikel
|
| 39 |
PSA testing for prostate cancer screening – Authors' reply
|
Cuzick, Jack
|
|
2015
|
16 |
1 |
p. e3-
1 p.
|
artikel
|
| 40 |
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|
Topp, Max S
|
|
2015
|
16 |
1 |
p. 57-66
10 p.
|
artikel
|
| 41 |
Silencing the voice of scientific reason
|
Lawler, Mark
|
|
2015
|
16 |
1 |
p. e4-e5
nvt p.
|
artikel
|
| 42 |
Skeletal muscle anabolism in patients with advanced cancer
|
Baracos, Vickie E
|
|
2015
|
16 |
1 |
p. 13-14
2 p.
|
artikel
|
| 43 |
Smoking and mosaic Y chromosome loss
|
Burki, Talha Khan
|
|
2015
|
16 |
1 |
p. e12-
1 p.
|
artikel
|
| 44 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
|
Grignani, Giovanni
|
|
2015
|
16 |
1 |
p. 98-107
10 p.
|
artikel
|
| 45 |
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
|
Cuzick, Jack
|
|
2015
|
16 |
1 |
p. 67-75
9 p.
|
artikel
|
| 46 |
56th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2015
|
16 |
1 |
p. 19-20
2 p.
|
artikel
|
| 47 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
|
Finn, Richard S
|
|
2015
|
16 |
1 |
p. 25-35
11 p.
|
artikel
|
| 48 |
19th Society for Neuro-Oncology Annual Meeting
|
Collingridge, David
|
|
2015
|
16 |
1 |
p. 18-
1 p.
|
artikel
|
| 49 |
Towards effective adjuvant treatment for urothelial cancer
|
Siefker-Radtke, Arlene O
|
|
2015
|
16 |
1 |
p. 9-10
2 p.
|
artikel
|
| 50 |
UK Cancer Drugs Fund to reassess 42 agents
|
Cagney, Hannah
|
|
2015
|
16 |
1 |
p. e8-
1 p.
|
artikel
|
| 51 |
UK committee recommends HPV vaccination for MSM
|
Kirby, Tony
|
|
2015
|
16 |
1 |
p. e7-
1 p.
|
artikel
|
| 52 |
Undermining the Hippocratic Oath: the Medical Innovation Bill
|
The Lancet Oncology,
|
|
2015
|
16 |
1 |
p. 1-
1 p.
|
artikel
|
| 53 |
Use of a tumour bed boost as part of radiotherapy for breast cancer
|
Buchholz, Thomas A
|
|
2015
|
16 |
1 |
p. 5-6
2 p.
|
artikel
|
| 54 |
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
|
Bartelink, Harry
|
|
2015
|
16 |
1 |
p. 47-56
10 p.
|
artikel
|
Tijdschrift beschrijving